ATC Group: J01MB02 Nalidixic acid

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of J01MB02 in the ATC hierarchy

Level Code Title
1 J Antiinfectives for systemic use
2 J01 Antibacterials for systemic use
3 J01M Quinolone antibacterials
4 J01MB Other quinolones
5 J01MB02 Nalidixic acid

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 4 g

Active ingredients in J01MB02

Active Ingredient Description
Nalidixic acid

Nalidixic acid is a quinolone antibacterial agent for oral administration. Nalidixic acid and related drugs have been shown to cause arthropathy in juvenile animals of most species tested.

Medicines in this ATC group

Brazil (BR)

South Africa (ZA)

Turkey (TR)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.